Clinical Trials Sponsored by AJU Pharm Co., Ltd.

Total 653 results

Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

Primary Immune Thrombocytopenia

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Treatment-naїve Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Solid Tumors

China
Changzhou Qianhong Bio-pharma Co., Ltd.

Completed

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Acute Ischemic Stroke

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

MZL

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
EA Pharma Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants

Healthy Volunteers

United Kingdom
Hangzhou Zede Pharma-Tech Co., Ltd.

Completed

Short-term Clinical Study of CN128 in Thalassemia Patients

Thalassemia

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

China, United States, Ukraine, Poland
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Healthy Subject

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

DDI Study of Orelabrutinib

Healthy Person

China
UCB Japan Co. Ltd.

Completed

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

Epilepsies | Partial

Japan
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

ADME Study of [14C]ICP-022 in Healthy Males

Healthy Volunteers

China
Tianjin XinChen-Techfields Pharma Co., LTD.

Completed

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

KNEE OSTEOARTHRITIS

China
Hangzhou Zede Pharma-Tech Co., Ltd.

Completed

Clinical Study of CN128 in Thalassemia Patients

Thalassemia

China
LEO Pharma
Tigermed Consulting Co., Ltd

Completed

Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population

Psoriasis Vulgaris

China
EA Pharma Co., Ltd.

Completed

A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants

Healthy Male Participants

United Kingdom
EA Pharma Co., Ltd.

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State

Healthy Participants

United Kingdom
EA Pharma Co., Ltd.

Withdrawn

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants

Healthy Participants
AbbVie
Meiji Seika Pharma Co., Ltd.

Completed

A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder

Obsessive Compulsive Disorder
EA Pharma Co., Ltd.

Completed

General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation

Chronic Constipation

Japan
UCB Korea Co., Ltd.

Completed

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Idiopathic Parkinson's Disease

Korea, Republic of
Korea UCB Co., Ltd.

Completed

Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy (OPTIMAL)

Epilepsy

Korea, Republic of
UCB Japan Co. Ltd.

Completed

A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures

Epilepsies, Partial

Japan
UCB Japan Co. Ltd.

Completed

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Rheumatoid Arthritis

Japan, Korea, Republic of, Taiwan
Beijing InnoCare Pharma Tech Co., Ltd.

Not yet recruiting

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematologic Malignancies

China
Beijng Immunoah Pharma Tech Co., Ltd.

Recruiting

Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors

Recurrent or Metastatic, Advanced Solid Tumors

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma

Relapsed/Refractory Marginal Zone Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Hematological Malignancies

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

Advanced Solid Tumors and Hematologic Malignancies

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

DLBCL

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis

Psoriasis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-033 in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Hangzhou Zede Pharma-Tech Co., Ltd.

Recruiting

Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients

Iron Overload | Thalassemia

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma (BELIEVE-01)

Diffuse Large B Cell Lymphoma (DLBCL)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Bladder Urothelial Cancer

China
EA Pharma Co., Ltd.

Completed

A Study of E6011 in Participants With Active Crohn's Disease

Crohn's Disease

Czechia, Hungary, Japan, Poland, Russian Federation
Changzhou Qianhong Bio-pharma Co., Ltd.

Completed

Study to Assess PK, Safety and Tolerability Early in Healthy Subjects

Acute Ischemic Stroke

China
Takeda
Takeda Pharma Korea Co. Ltd.

Completed

Post Marketing Surveillance Study for ADYNOVATE in South Korea

Hemophilia A

Korea, Republic of
Hangzhou Zede Pharma-Tech Co., Ltd.

Completed

Long-term Clinical Study of CN128 in Thalassemia Patients

Iron Overload | Thalassemia

China
UCB Japan Co. Ltd.

Completed

A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age (PEACH)

Partial Seizures

Japan
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Part 1：r/r B-cell Malignancies | Part 2：B-cell Malignancies

United States, Poland, Israel, Ukraine
Jiangsu XinChen-Techfields Pharma Co., LTD.

Completed

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

KNEE OSTEOARTHRITIS

China
Sumitomo Pharma (Suzhou) Co., Ltd.
Sunovion

Terminated

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

Bipolar I Depression

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL

PCNSL | Secondary Central Nervous System Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

Healthy Subjects

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With CLL/ SLL

CLL/SLL

China

3

Subscribe